Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Halozyme rockets 30% on potential $515M deal with Pfizer

This article was originally published in Scrip

Executive Summary

Shares of Halozyme Therapeutics soared 30% on 21 December after it revealed it had inked a worldwide deal with Pfizer to develop and commercialize subcutaneous biologics using recombinant human hyaluronidase.

Advertisement

Related Content

Halozyme's 2017 Includes PEGPH20 Milestones, New Partnership

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC019880

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel